Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 8.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 92,897 shares of the company’s stock after selling 8,070 shares during the period. Rhumbline Advisers owned about 0.16% of Twist Bioscience worth $4,578,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Artisan Partners Limited Partnership grew its stake in Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after purchasing an additional 1,961,621 shares in the last quarter. Norges Bank bought a new stake in shares of Twist Bioscience in the fourth quarter worth $10,766,000. Dimensional Fund Advisors LP raised its holdings in Twist Bioscience by 29.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after acquiring an additional 284,884 shares in the last quarter. Baillie Gifford & Co. boosted its stake in Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock valued at $42,116,000 after acquiring an additional 132,770 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in Twist Bioscience by 523.1% during the 1st quarter. Jennison Associates LLC now owns 150,022 shares of the company’s stock worth $5,147,000 after acquiring an additional 125,946 shares in the last quarter.

Twist Bioscience Stock Up 5.3 %

TWST stock opened at $46.95 on Monday. The stock has a market cap of $2.75 billion, a PE ratio of -13.97 and a beta of 1.76. The firm’s 50-day simple moving average is $47.68 and its 200 day simple moving average is $42.77. Twist Bioscience Co. has a fifty-two week low of $14.42 and a fifty-two week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. Twist Bioscience’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.01) EPS. Equities analysts forecast that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TWST. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Robert W. Baird lifted their target price on Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research report on Monday, August 5th. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. The Goldman Sachs Group lifted their price objective on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Finally, TD Cowen increased their target price on shares of Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.22.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,732 shares of the stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $49.41, for a total value of $85,578.12. Following the completion of the transaction, the chief executive officer now owns 505,846 shares of the company’s stock, valued at $24,993,850.86. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Emily M. Leproust sold 1,732 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $49.41, for a total value of $85,578.12. Following the completion of the sale, the chief executive officer now owns 505,846 shares of the company’s stock, valued at $24,993,850.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,114 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total transaction of $53,472.00. Following the transaction, the chief executive officer now directly owns 504,732 shares in the company, valued at approximately $24,227,136. The disclosure for this sale can be found here. Insiders have sold 17,388 shares of company stock valued at $776,599 in the last quarter. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.